Edmonton, Alberta--(Newsfile Corp. - October 3, 2023) - Pacylex Pharmaceuticals, a clinical stage pharmaceutical company focused on the development of therapies for hematologic and solid cancers, announced recent results generated at NIH using its lead drug, zelenirstat, presented at the Canadian Association of Radiation Oncology Annual Meeting in Montreal, Canada, on September 23, 2023.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Zelenirstat, a myristoylation inhibitor in clinical development, markedly improved the ability of radiation to kill cultured human brain cancer cells.
- Zelenirstat was more effective than clinically used radiosensitizers, including temozolomide, cisplatin, and 5-fluorouracil.
- Orally administered zelenirstat is predicted to cross the blood brain barrier more efficiently than temozolomide, the current standard of care radiosensitizer for aggressive brain cancers.
Click image above to view full announcement.
About Zelenirstat
Zelenirstat (formerly identified as PCLX-001) is a first-in-class, oral, small molecule N-myristoyltransferase (NMT) inhibitor being developed to treat patients with leukemia, lymphoma, and solid tumors. Zelenirstat selectively kills cancer cells in vitro and has been shown to regress hematologic malignancies and inhibit the growth of lung and breast cancer tumors in animal models. Zelenirstat is particularly effective against Diffuse Large B Cell Lymphoma (DLBCL) and Acute Myeloid Leukemia (AML) in animal disease models. In AML, it also selectively kills leukemic stem cells in vivo while sparing normal bone marrow cells.Zelenirstat is currently being evaluated in a Phase 1/2a open-label study (NCT04836195) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of zelenirstat in patients with relapsed/refractory (R/R) Non Hodgkin Lymphoma (NHL) and advanced solid malignancies who have progressed on all available standard therapies.
About Pacylex Pharmaceuticals
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with orally bioavailable NMT inhibitors. Pacylex has a US Subsidiary in the San Francisco Bay area. Zelenirstat is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex is conducting a multi-center Phase 1 multiple ascending dose study in Canada in patients with R/R NHL and advanced solid tumors, and a Phase 2a dose expansion in patients with R/R NHL. The IND for a Phase 1 multiple ascending dose study in AML has been cleared and the FDA has granted zelenirstat both Orphan Drug Designation and Fast Track Designation for AML. The US Department of Defense is supporting the initial clinical investigation of zelenirstat in patients with AML. The Cure Cancer Foundation supported initial clinical studies through its World's Longest Games.
For additional information, please visit www.pacylex.com.
Twitter @Pacylex (https://twitter.com/pacylex)
LinkedIn (www.linkedin.com/company/pacylex-pharma)
Facebook (https://www.facebook.com/pacylex)
Contacts:
Michael Weickert Ph.D
650-218-1840
michael.weickert@pacylex.com
Source: Pacylex
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/182787
